These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16224405)

  • 1. CC-5013 MM 0017: a multicenter, randomized, parallel-group, double-blind, placebo-controlled study of CC-5013 plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma.
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):189-90. PubMed ID: 16224405
    [No Abstract]   [Full Text] [Related]  

  • 2. Eastern Cooperative Oncology Group E1A00: phase III randomized study of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma.
    Greipp PR
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):188-9. PubMed ID: 16224404
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
    Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R
    Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G
    Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma.
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):190. PubMed ID: 16235416
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
    Rajkumar SV; Blood E; Vesole D; Fonseca R; Greipp PR;
    J Clin Oncol; 2006 Jan; 24(3):431-6. PubMed ID: 16365178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
    Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
    Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
    Rajkumar SV
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD.
    Milone JH; Prates V; Bordone J; Napal J; Garcia C
    Bone Marrow Transplant; 2003 Aug; 32(3):343. PubMed ID: 12858210
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel agents in myeloma: an exciting saga.
    Mark T; Niesvizky R; Coleman M
    Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986
    [No Abstract]   [Full Text] [Related]  

  • 17. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
    Lokhorst HM; Schmidt-Wolf I; Sonneveld P; van der Holt B; Martin H; Barge R; Bertsch U; Schlenzka J; Bos GM; Croockewit S; Zweegman S; Breitkreutz I; Joosten P; Scheid C; van Marwijk-Kooy M; Salwender HJ; van Oers MH; Schaafsma R; Naumann R; Sinnige H; Blau I; Delforge M; de Weerdt O; Wijermans P; Wittebol S; Duersen U; Vellenga E; Goldschmidt H; ;
    Haematologica; 2008 Jan; 93(1):124-7. PubMed ID: 18166796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
    Richardson P; Anderson K
    J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.